

Appendix: Detailed assumptions for treatment

Acute Treatments for cardiovascular disease

Acute MI or unstable angina will be treated with aspirin (initial dose of 325 mg then 75-100 mg daily), heparin (12,500U SC bid for 3 days, supplied as 10,000 U/ml), and glyceryl trinitrate (estimated average of 5 doses of 0.3 mg over 3 days per patient, given as needed), as well as the morphine that is already in the IEHK (1). Electrocardiography equipment would be desirable. Thrombolytic treatment is not practical in emergency settings.

Acute stroke will be treated with aspirin (150-350 mg daily) (2).

Acute heart failure will be treated with glyceryl trinitrate (estimated average of 5 doses of 0.3 mg over 3 days per patient, given as needed) and furosemide (estimated average of 80 mg) as well as the morphine that is already in the IEHK (3-5).

Treatments after stabilization of cardiovascular disease

After being stabilized, patients with acute MI or unstable angina will be treated with aspirin (75-100 mg daily), atenolol (50 mg daily), enalapril (5 mg bid) and simvastatin (20 mg daily) (6) and will be given a 90 day supply. Similar considerations will apply to patients presenting with stable coronary disease (scenario 2).

After being stabilized, patients with stroke or TIA will be treated with aspirin (75-100 mg daily) (7) and simvastatin (20 mg daily) (8) and will be given a 90 day supply. Most

patients will receive enalapril 5 mg BID either for treatment of hypertension or for secondary prevention of vascular disease (9). Similar considerations will apply to stable patients presenting with prior stroke (scenario 2).

After being stabilized, patients with acute MI, stroke or TIA will receive add-on treatment with hydrochlorothiazide (12.5 mg daily) if blood pressure is >140/90 (10) despite enalapril 5 mg bid (anticipated to occur in 33% of patients), and will be given a 90 day supply. Third line agents will not be added. Higher achieved blood pressures will be accepted in some patients but this would not be expected to materially affect the estimated quantity of medications required.

After being stabilized, patients with acute heart failure will be treated with enalapril (10 mg bid) (11), atenolol (11) and furosemide (80 mg daily) and will be given a 90 day supply. Although low atenolol will be initiated at low dose (12.5 mg daily) after enalapril treatment is established and titrated up, 50 mg doses daily have been used when estimating dose requirements, since this does not materially influence costs or space requirements in the IEHK, and titration regimens will vary. Similar considerations will apply to patients presenting with stable heart failure (scenario 2), although we have assumed that such patients will not require atenolol treatment if clinically stable. Spironolactone will not be given due to the risk of hyperkalemia.

Treatments for diabetes

Acute severe hypoglycemia in people with known diabetes will be treated with two ampoules of dextrose 50% and with 5% dextrose infusion if required. Diabetic ketoacidosis or hyperosmotic non-ketotic hyperglycemia will be suspected in patients with blood glucose >18 mmol/l and treated with insulin (expected average requirement of 60 units per case) and intravenous fluids.

Once stabilized, adults and children with hyperglycemia syndromes will be treated with insulin and given a 90-day supply (average of 30U or 20 U for adults and children respectively per day of 30/70 insulin, supplied as 10 ml vials of 100U/ml: an average of 3 vials per adult user and 2 vials per child user).

For scenario 2, children with stable diabetes will be assumed to require insulin at the dose above. Adults will be assumed to require oral hypoglycemic agents. Although metformin is contraindicated when kidney function is severely impaired (estimated glomerular filtration rate <30 ml/min/1.73m²), this level of kidney dysfunction is relatively uncommon and therefore we have assumed that metformin (2.5 g/d) will be the first line agent for all adult patients presenting with stable diabetes. Glibenclamide (2.5 mg daily) will be added if needed to achieve glycemic control and has been assumed necessary in 25% of patients.

Routine home laboratory monitoring of glycemic control will not be provided. An average of one glucose test strip per patient per week will be made available for checking glucose at the time of clinic visits.

Treatments for hypertension

Hypertensive emergency is defined by blood pressure $>200/120$ plus the presence of symptoms such as headache, confusion or coma; or other symptoms of end-organ damage. It will be managed using the intravenous hydralazine that is already in the IEHK together with oral antihypertensive agents (enalapril 10 mg bid, hydrochlorothiazide 12.5 mg daily, amlodipine 10 mg daily, atenolol 50 mg daily). Although other definitions of hypertensive emergency exist, using an alternative definition would not be expected to materially influence the estimates of the medication quantities required for the IEHK.

Severe hypertension (hypertensive urgency) is defined by extremely high blood pressure (levels not specified, but on the order of $>200/120$) without symptoms and can be managed by the addition of oral medication (enalapril, hydrochlorothiazide, amlodipine, atenolol as needed, same doses as above).

Once stabilized, patients with hypertensive emergency or urgency will be managed with oral antihypertensive agents (enalapril, hydrochlorothiazide, amlodipine, atenolol as needed, same doses as above) and given a 90 day supply.

Hypertension in pregnancy will be managed with the methyldopa that is already available in the IEHK. Amlodipine 5 mg daily will be added if needed.

For purposes of estimating the required quantities of medications, we assumed that the usual sequence of oral drugs for chronic control of hypertension would be enalapril, hydrochlorothiazide, then amlodipine or atenolol. However, clinicians are free to use an alternative order at their discretion.

Treatment for chronic respiratory disease

Patients with acute asthma exacerbations will receive prednisolone (estimated dose requirements 30 mg for five days for adults and 20 mg for three days for children), and inhaled salbutamol (100 mcg bid) (12).

Once stabilized, patients with asthma will be treated with short acting bronchodilator (salbutamol 100 mcg bid as needed) and inhaled beclomethasone (100 mcg bid), and given a 90 day supply (12). Similar considerations will apply to patients presenting with stable asthma (scenario 2).

Acute exacerbations of COPD will be treated with oral amoxicillin (already in the IEHK), and oral prednisolone 30 mg for seven days (13).

Once stabilized, patients with COPD and a history of exacerbations should be treated with short acting bronchodilator (salbutamol 100 mcg qid as needed) and inhaled beclomethasone (100 mcg bid), and given a 90 day supply. Although some physicians reserve the use of beclomethasone treatment for patients with a history of multiple COPD exacerbations, this will not materially influence costs or space requirements in the IEHK

(13). Similar considerations will apply to patients presenting with stable chronic respiratory disease (scenario 2). Long acting bronchodilators will not be used given uncertainties about how to identify patients who would optimally benefit.

Appendix Table: Data sources

Citation	Incidence of acute presentation	Prevalence of chronic presentation	Note
Deshmukh 2011 (14)	Adults with hypertensive emergency		
Zampaglione 1996 (15)	Adults with hypertensive urgency		Hypertensive urgencies are 3 times as common as emergencies
Danaei 2011 (16)		Adults with hypertension	
Li 2014 (17)	Adults with severe hyperglycemia		
Li 2014 (17)	Adults with severe hypoglycemia		
Rewers 2002 (18)	Children with severe hyperglycemia		
Rewers 2002 (18)	Children with severe hypoglycemia		
Danaei 2011 (19)		Adults with diabetes	
American Diabetes Association (6)		Children with diabetes	4% of all diabetes is Type 1
Moran 2014 (20)	Adults with acute MI		Incidence of acute MI is 3 times as common in emergencies (21-25)
Moran 2014 (20)		Adults with coronary disease	
Feigin 2014 (26)	Adults with acute stroke		Incidence of stroke is 2 times as common in emergencies (21-25)
Feigin 2014 (26)		Adults with cerebrovascular disease	

Citation	Incidence of acute presentation	Prevalence of chronic presentation	Note
Blecker 2014 (27) Moran 2014 (20) Akinbami 2011 (28) Akinbami 2011 (28) Burney 2015 (29) Centers for Disease Control and Prevention (30) Hurst 2010 (31) Buist 2007 (32)	Adults with heart failure Adults with asthma attacks Children with asthma attacks Adults with COPD exacerbation	Adults with heart failure Adults with asthma Children with asthma Adults with COPD	

Population estimates (total and distribution of adults and children) were drawn from the United Nations' Department of Economic and Social Affairs Population Division, the 2013 Revision (esa.un.org/unpd/wpp/Download/Standard/Population).

References

1. Timmis A. Acute coronary syndromes. *BMJ*. 2015;351:h5153.
2. Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141:e601S-36S.
3. Heart Failure Society of A, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. *J Card Fail*. 2010;16:e1-194.
4. Writing Committee M, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation*. 2013;128:e240-327.
5. Stampfer M, Epstein SE, Beiser GD, Braunwald E. Hemodynamic effects of diuresis at rest and during intense upright exercise in patients with impaired cardiac function. *Circulation*. 1968;37:900-11.
6. American Diabetes Association. Statistics About Diabetes. 2015; <http://www.diabetes.org/diabetes-basics/statistics/>. Accessed April 1, 2015.
7. Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*. 2002;324:71-86.
8. Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. *Neurology*. 2007;69:904-10.
9. Lee M, Saver JL, Hong KS, Hao Q, Chow J, Ovbiagele B. Renin-Angiotensin system modulators modestly reduce vascular risk in persons with prior stroke. *Stroke*. 2012;43:113-9.
10. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014;311:507-20.
11. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013;62:e147-239.
12. National Asthma Education and Prevention Program. Expert Panel Report III: Guidelines for the diagnosis and management of asthma. 2007; <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>. Accessed November 30, 2015.
13. The Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD: Revised 2014. 2014; http://www.goldcopd.org/uploads/users/files/GOLD_Report2014_Feb07.pdf. Accessed April 1, 2015.
14. Deshmukh A, Kumar G, Kumar N, et al. Effect of Joint National Committee VII report on hospitalizations for hypertensive emergencies in the United States. *Am J Cardiol*. 2011;108:1277-82.
15. Zampaglione B, Pascale C, Marchisio M, Cavallo-Perin P. Hypertensive urgencies and emergencies. Prevalence and clinical presentation. *Hypertension*. 1996;27:144-7.

16. Danaei G, Finucane MM, Lin JK, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. *Lancet*. 2011;377:568-77.
17. Li J, Yang D, Yan J, et al. Secondary diabetic ketoacidosis and severe hypoglycaemia in patients with established type 1 diabetes mellitus in China: a multicentre registration study. *Diabetes Metab Res Rev*. 2014;30:497-504.
18. Rewers A, Chase HP, Mackenzie T, et al. Predictors of acute complications in children with type 1 diabetes. *JAMA*. 2002;287:2511-8.
19. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. *Lancet*. 2011;378:31-40.
20. Moran AE, Forouzanfar MH, Roth GA, et al. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. *Circulation*. 2014;129:1493-501.
21. Kario K. Disaster hypertension - its characteristics, mechanism, and management. *Circ J*. 2012;76:553-62.
22. Kenerson JG. Hypertension in Haiti: the challenge of best possible practice. *J Clin Hypertens (Greenwich)*. 2014;16:107-14.
23. Peters MN, Moscona JC, Katz MJ, et al. Natural disasters and myocardial infarction: the six years after Hurricane Katrina. *Mayo Clin Proc*. 2014;89:472-7.
24. Tanaka K, Nakayama M, Kanno M, et al. Home blood pressure control after the great East Japan earthquake in patients on chronic hemodialysis. *Ther Apher Dial*. 2014;18:149-54.
25. Trichopoulos D, Katsouyanni K, Zavitsanos X, Tzonou A, Dalla-Vorgia P. Psychological stress and fatal heart attack: the Athens (1981) earthquake natural experiment. *Lancet*. 1983;1:441-4.
26. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. *Lancet*. 2014;383:245-54.
27. Blecker S, Ladapo JA, Doran KM, Goldfeld KS, Katz S. Emergency department visits for heart failure and subsequent hospitalization or observation unit admission. *Am Heart J*. 2014;168:901-8 e1.
28. Akinbami LJ, Moorman JE, Liu X. Asthma prevalence, health care use, and mortality: United States, 2005-2009. *Natl Health Stat Report*. 2011:1-14.
29. Burney P, Jarvis D, Perez-Padilla R. The global burden of chronic respiratory disease in adults. *Int J Tuberc Lung Dis*. 2015;19:10-20.
30. Centers for Disease Control and Prevention. Data, Statistics, and Surveillance - Asthma Surveillance Data. 2015; <http://www.cdc.gov/asthma/asthadata.htm>. Accessed April 1, 2015.
31. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med*. 2010;363:1128-38.
32. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. *Lancet*. 2007;370:741-50.